The experimental antitumor agents phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models

Breast Cancer Research and Treatment

Volumn 87, Issue 1, 2004, Pages 97-107

  Fichtner, Iduna ^a   Monks, Anne ^b   Hose, Curtis ^b   Stevens, Malcolm F G ^c   Bradshaw, Tracey D ^c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

breast carcinoma model; cytochrome P450 1A1; doxorubicin; estrogen receptor; Phortress

Indexed keywords

2 (4 AMINO 3 METHYLPHENYL) 5 FLUOROBENZOTHIAZOLE LYSINAMIDE; 5 FLUORO 2 (4 LYSYLAMINO 3 METHYLPHENYL)BENZOTHIAZOLE; ANTINEOPLASTIC AGENT; CYTOCHROME P450 1A1; DOXORUBICIN; MESSENGER RNA; NSC 710305; PRODRUG; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; GENE INDUCTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CYTOCHROME P-450 CYP1A1; DNA ADDUCTS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PRODRUGS; THIAZOLES; TRANSPLANTATION, HETEROLOGOUS;

EID: 4544294382     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000041586.64371.88     Document Type: Article

References (25)

1. Bradshaw TD, Chua M-S, Browne HL, Trapani V, Sausville EA, Stevens MFG: In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Brit J Cancer 86: 1348-1354, 2002
2. Bradshaw TD, Fichtner I, Bibby MJ, Double JA, Cooper PA, Alley MC, Tomaszewjski JE, Donahue S, Stinson SF, Sausville EA, Stevens MFG: Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl) benzothiazoles. Mol Can Therapeutics 1: 239-246, 2002
3. Alley MC, Stinson SF, Pacula-Cox CM, Upadhyay KB, Bradshaw TD, Chua M-S, Stevens MFG, Sausville E: A. Pharmacologic evaluations of fluorinated 2-(4-aminophenyl)benzothiazole analogs with unique anticancer activities. Proc AACR 44: #5166, 2000
4. Loaiza-Perez AI, Trapani V, Hose C, Singh SS, Trepel J, Stevens MFG, Bradshaw TD, Sausville EA: The AhR mediates sensitivity of MCF-7 breast cancer cells to the antitumor agent 2-(4-amino-3-methylphenyl)benzothiazole. Molecular Pharmacol 61: 13-19, 2002
5. Chua M-S, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MFG: Role of CYP1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 60: 5196-5203, 2000
6. Hutchinson I, Chua M-S, Browne HL, Trapani V, Bradshaw TD, Stevens MFG: Antitumor benzothiazoles. 14. The synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem 44: 1446-1455, 2001
7. Monks A, Harris E, Hose C, Connelly J, Sausville A: Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5- fluorobenzothiazole. Mol Pharmacol 6: 766-772, 2003
8. Leong C-O, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC, Cooper PA, Double JA, Bradshaw TD, Stevens MFG: Antitumour 2-(4-aminophenyl) benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Brit J Cancer 88: 470-477, 2003
9. Guengerich FP: The Bernard B Brodie award lecture: bioactivation and detoxification of toxic and carcinogenic chemicals. Drug Metab Dispos 21: 1-6, 1993
10. Hansen LG, Shane BS, Xenibiotic metabolism. In: Cockerham LG, Shane BS (eds) Basic Environmental Toxicology, CRC Press, Boca Raton, FL, 1994, pp 49-105
11. Crofts FG, Sutter TR, Strickland PT: Metabolism of 2-amino-1-methyl-6- phenylimidazo[4, 5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis (Lond) 19: 1969-1973, 1998
12. http://www.cancerresearchuk.org
13. William B, Pratt WB: In: The Anticancer Drugs. 2nd edn. Oxford University Press, New York, 1994
14. Hutchinson I, Jennings SA, Vishnuvajjala BR, Westwell AD, Stevens MFG: Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs. J Med Chem 45: 744-747, 2002
15. Soule HD, Vazquez J, Long A, Albert S, Brennan, M: A human cell line from a pleural effusion derived from a breast carcinoma. JNCI 51: 1409, 1973
16. Naundorf H, Fichtner I, Buttner B, Frege, J: Establishment and characterization of a new human estradiol- and progesterone-receptor-positive mammary carcinoma serially transplantable in nude mice. J Cancer Res Clin Oncol 119: 35-40, 1992
17. Naundorf H, Becker M, Lykkesfeldt AE, Elbe B, Neumann C, Buttner B, Fichtner I: Development and characterization of a tamoxifen resistant breast carcinoma xenograft. Brit J Cancer 82: 1844-1850, 2000
18. Fichtner I, Naundorf H, Saul GJ, Zschiesche W, Zeisig R: Establishment and characterization of human xenotransplanted breast carcinoma lines: use for the screening of alkylphosphocholines (APC). In: Arnold W, Kopf-Maier P, Micheel B (eds) Immunodeficient Animals: Models for Cancer Research. Contrib Oncol Basel, Karger 51: 129-133, 1996
19. Naundorf H, Fichtner I, Elbe B, Saul GJ, Haensch W, Zschiesche W, Reinecke S: Establishment and characteristics of two new human mammary carcinoma lines in nude mice with special reference to the estradiol receptor status and the importance of stroma for in vivo and in vitro growth. Breast Cancer Res Treat 32: 187-196, 1994
20. Naundorf H, Fichtner I, Saul GJ, Haensch W, Buttner, B: Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice. J Cancer Res Clin Oncol 119: 652-656, 1993
21. Shi D-F, Bradshaw TD, Wrigley S, McCall CJ, Lelieveld P, Fichtner I, Stevens MFG: Antitumor Benzothiazoles. 3. Synthesis of 2-(4-aminophenyl) benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J Med Chem 39: 3375-3384, 1996
22. Bradshaw TD, Wrigley S, Shi D-F, Schultz RJ, Paull KD, Stevens MFG: 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro and in vivo activity. Brit J Cancer 77: 745-752, 1998
23. Bradshaw TD, Chua M-S, Orr S, Matthews CS, Stevens, MFG: Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445). Brit J Cancer 83: 270-277, 2000
24. Hose C, Hollingshead M, Sausville EA, Monks A: Induction of CYP1A1 in tumor cells by the antitumor agent 2-(4-amino-3-methyl)-5-fluorobenzothiazole: a potential surrogate marker for patient sensitivity. Mol Can Therapeutics 2: 1265-1272, 2003
25. Vickers PJ, Dickens RB, Shoemaker R, Cowan KH: A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 2: 886-892, 1988